UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000030108
Receipt number R000034376
Scientific Title Clinical study on the usefullness of edoxaban tosilate hydrate to portal vein thrombosis complicated with chronic liver disease
Date of disclosure of the study information 2017/11/24
Last modified on 2019/05/27 20:23:22

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical study on the usefullness of edoxaban tosilate hydrate to portal vein thrombosis complicated with chronic liver disease

Acronym

PVTED study

Scientific Title

Clinical study on the usefullness of edoxaban tosilate hydrate to portal vein thrombosis complicated with chronic liver disease

Scientific Title:Acronym

PVTED study

Region

Japan


Condition

Condition

Portal vein thrombosis

Classification by specialty

Hepato-biliary-pancreatic medicine Hepato-biliary-pancreatic surgery

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Evaluate the usefulness of edexaban tosilate hydrate for portal vein thrombosis associated with chronic liver disease.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Reduction rate of portal vein thrombus 14 days after edoxaban administration

Key secondary outcomes

Safety of edoxaban administration against portal vein thrombosis


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Edoxaban 30 to 60 mg / day for 14 days

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

1) Clinically (histologically or imagewise) diagnosed as chronic liver disease.
2) Patients who have been confirmed to have thrombus in the portal vein, superior mesenteric vein, or / and splenic vein on the image.
3) The latest inspection value within 14 days before registration (same day as two weeks before the registration day is acceptable) satisfies all of the following.
Hemoglobin 9.0 g / dl or more (male), 8.0 g / dl or more (female)
Platelet count 50,000 / mm 3 or more
Creatinine clearance 30 ml / min or more
4) Child-Pugh classification A or B.
5) Weight 40 kg or more.
6) About participation in the examination Informed consent is obtained from the patient himself.

Key exclusion criteria

1. Child-Pugh classification C.
2. Endoscopic examination confirms the presence of lesions at risk of gastrointestinal bleeding (esophageal gastric varices, gastric / duodenal ulcers, gastric antral vascular dilation, etc.), and does not perform prophylactic treatment.
3. Have active malignancy.
4. Patients taking anticoagulant or / and antiplatelet drugs.
5. Patients with a history of clear bleeding symptoms such as cerebral haemorrhage.
6. Patients who weigh less than 40 kg at registration.
7. A woman who is pregnant or has a possibility of pregnancy, within 28 days after childbirth or breast-feeding. A man who wishes to become a partner's pregnant.
8. Mental illness or psychiatric symptoms are merged and it is judged that participation in the examination is difficult.
9. It has severe hypersensitivity to the ingredients of Edoxaban.
10. Because of drug allergy, neither CT nor MRI using a contrast agent can be performed.
11. Others, the doctor in charge determines that participation in this examination is inappropriate.

Target sample size

20


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Shuichi Kaneko

Organization

Kanazawa University Hospital

Division name

Gastroenterology / Hepatobiliary and pancreatic surgery

Zip code


Address

13-1,Takara-machi,Kanazawa city

TEL

076-265-2000

Email

skaneko@m-kanazawa.jp


Public contact

Name of contact person

1st name
Middle name
Last name Hajime Takatori

Organization

Kanazawa University Hospital

Division name

Gastroenterology

Zip code


Address

13-1,Takara-machi,Kanazawa city

TEL

076-265-2000

Homepage URL


Email

takatori@m-kanazawa.jp


Sponsor or person

Institute

Kanazawa University Hospital

Institute

Department

Personal name



Funding Source

Organization

Kanazawa University Hospital

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 11 Month 24 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2017 Year 10 Month 26 Day

Date of IRB

2017 Year 12 Month 12 Day

Anticipated trial start date

2017 Year 12 Month 18 Day

Last follow-up date

2019 Year 05 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 11 Month 24 Day

Last modified on

2019 Year 05 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034376


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name